Lapatinib Powder

Product Details

Lapatinib powder is a new drug for breast cancer targeted therapy developed by GlaxoSmithKline, UK. It is a tyrosine kinase inhibitor that can effectively inhibit human epidermal growth factor receptor-1 (ErbB1) and human epidermal growth factor Receptor-2 (ErbB2) tyrosine kinase activity. It is unique in that it acts in a number of ways, preventing breast cancer cells from receiving the signals they need to grow.

Lapatinib, in combination with capecitabine, is indicated for the treatment of patients with HER2 (ErbB-2 overexpressing) advanced or metastatic breast cancer who have received prior therapy including anthracyclines, paclitaxel, and trastuzumab.

Raw materials lapatinib powder has a different mechanism of action from the approved humanized monoclonal antibody drug Herceptin, which can downregulate cell proliferation signals by double blocking the HER-1/HER-2 pathway. The clinical indication is combined with capecitabine in the treatment of advanced or metastatic breast cancer with HER2 overexpression and previous treatment including anthracyclines, taxanes and trastuzumab. The effective rate of late-stage first-line monotherapy is about 12-24%. General clinical guidelines recommend second-line drugs. The effective rate of combined treatment with capecitabine is about 26-33%, and the clinical benefit rate is up to 71.3%.

Health Benefits

Lapatinib is a 4-aniline quinazoline kinase inhibitor that selectively and reversibly inhibits the epidermal growth factor receptor and human epidermal receptor 2 in the intracellular tyrosine kinase domain. In vitro experiments and various animal models, the drug can inhibit the growth of tumor cells induced by epidermal growth factor receptor.